Product Description
A fully human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Seribantumab binds to binds to and inhibits ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/seribantumab)
Mechanisms of Action: ERBB3 Activator
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Oncology Solid Tumor Unspecified *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merrimack
Company Location: CAMBRIDGE MA 02142
Company CEO: Gary L. Crocker
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer|Uterine Cancer|Colorectal Cancer|Ovarian Cancer|Head and Neck Cancer|Lung Cancer|Sarcoma|Triple Negative Breast Cancer|Gallbladder Cancer|Cholangiocarcinoma|Prostate Cancer|Esophageal Cancer|Peritoneal Cancer|Pancreatic Cancer|Kidney Cancer|Bile Duct Cancer|Fallopian Tube Cancer
Phase 1: Colorectal Cancer|Ovarian Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Breast Cancer|Endometrial Cancer|Non-Small-Cell Lung Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CRESTONE | P2 |
Terminated |
Ovarian Cancer|Kidney Cancer|Head and Neck Cancer|Esophageal Cancer|Gallbladder Cancer|Prostate Cancer|Cholangiocarcinoma|Uterine Cancer|Colorectal Cancer|Sarcoma|Breast Cancer|Lung Cancer|Bile Duct Cancer|Pancreatic Cancer |
2024-02-28 |
|
| TOHCC-OLIP-01 | P2 |
Completed |
Pancreatic Cancer |
2021-12-22 |
|
| 2017-000565-76 | P2 |
Terminated |
Breast Cancer |
2020-09-05 |
|
| SHERLOC | P2 |
Terminated |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2019-01-02 |